Skip to content

Case-control study, 2000

Do women with PMS have different hormone levels than women without PMS?

Yes. Women with PMS have significantly lower levels of allopregnanolone and progesterone, especially during the second half of the menstrual cycle. Their bodies also showed a weaker response to a hormone stimulation test.

Moderate study design 56 women aged 18 to 32 years (28 with PMS, 28 controls)

What they did

Measured blood hormone levels in 28 women with PMS and 28 control women without PMS during both phases of the menstrual cycle. Tested hormone response to stimulation in a subset of each group.

What they found

In the luteal phase, allopregnanolone and progesterone were significantly lower in women with PMS compared to controls. Progesterone was also lower during the follicular phase in women with PMS. Estradiol levels were in the normal range for both groups but slightly higher in those with PMS. The hormone response to stimulation was significantly weaker in women with PMS.

What it means for you

Women with PMS may produce inadequate amounts of brain-active steroids, particularly in the luteal phase, which could affect mood and anxiety regulation. This could explain why some women develop PMS while others don't. The study included only young women aged 18 to 32, so results may not apply to all ages.

28

women with PMS

28

control women

18-32

age range in years

About the study

Original title
Allopregnanolone concentrations and premenstrual syndrome
Authors
Monteleone P, Luisi S, Tonetti A et al.
Journal
European journal of endocrinology
Year
2000
Study design
Case-control study
Participants
56
What was tested
Hormone level measurement and stimulation test
Open access
Yes
Original abstract

Objective: To evaluate basal allopregnanolone and progesterone in both phases of the menstrual cycle in women suffering from premenstrual syndrome (PMS) and their response to a GnRH test. Design: We selected 56 women (28 patients with PMS and 28 controls) aged between 18 and 32 years. Blood samples were drawn in both follicular and phases. Twenty-eight women (14 patients with PMS and 14 controls) underwent a GnRH test in the luteal phase. Methods: We evaluated allopregnanolone by RIA, using a specific antibody. Serum progesterone and oestradiol were determined using a commercially available RIA kit. Results: Luteal phase allopregnanolone concentrations were significantly lower in patients with PMS than in controls. Progesterone concentrations were significantly lower in patients with PMS in both the follicular and the luteal phase. Serum oestradiol concentrations were in the normal range in both groups of women, although slightly greater in those with PMS. Allopregnanolone and progesterone responses to a GnRH test were significantly blunted in women with PMS. Conclusions: Diminished concentrations of allopregnanolone and progesterone, its precursor, and a blunted response to the GnRH test lead us to hypothesise that patients with PMS may suffer from an inadequate production of ovarian neuroactive steroids, especially in the luteal phase. This would lead to an impaired anxiolytic GABA(A)-mediated response in stressful physiological and psychological conditions, and may in part explain various psychoneuroendocrine symptoms that arise during PMS.

Reproduced under CC-BY.

Topics